DS
BDTX icon

David Shaw’s Black Diamond Therapeutics BDTX Stock Holding History

David Shaw’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$291K Sell
157,340
-206,581
-57% -$505K ﹤0.01% 4428
2026
Q1 		$775K Sell
363,921
-291,851
-45% -$694K ﹤0.01% 3599
2025
Q4 		$1.59M Buy
655,772
+512,129
+357% +$1.81M ﹤0.01% 3221
2025
Q3 		$544K Buy
143,643
+125,743
+702% +$368K ﹤0.01% 3822
2025
Q2 		$44.4K Buy
17,900
+46
+0.3% +$89 ﹤0.01% 4177
2025
Q1 		$27.7K Buy
17,854
+537
+3% +$1.13K ﹤0.01% 4090
2024
Q4 		$37.1K Buy
+17,317
New +$49.6K ﹤0.01% 4212

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

David Shaw's BDTX Position: Q2 2026 in Review

David Shaw reduced its Black Diamond Therapeutics (BDTX) stake by 57% in Q2 2026, selling an estimated $505K and leaving 157,340 shares worth $291K. The position accounts for ﹤0.01% of the portfolio, ranked #4428.

David Shaw first reported a position in BDTX in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.59M in Q4 2025. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

  • David Shaw held 157,340 shares of Black Diamond Therapeutics worth $291K as of Q2 2026.
  • David Shaw sold 206,581 Black Diamond Therapeutics shares in Q2 2026, an estimated $505K.
  • Black Diamond Therapeutics made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #4428 holding.
  • David Shaw first reported a position in Black Diamond Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • David Shaw's Black Diamond Therapeutics position peaked at $1.59M in Q4 2025.
  • 96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.